Literature DB >> 23403054

Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα) are both transcriptional regulators of the Runx2-I isoform.

Martial Kammerer1, Sabine Gutzwiller, Daniela Stauffer, Isabelle Delhon, Yves Seltenmeyer, Brigitte Fournier.   

Abstract

Runx2 is a master regulator of bone development and has also been described as an oncogene. Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα), both implicated in bone metabolism and breast cancer, have been shown to share common transcriptional targets. Here, we show that ERα is a positive regulator of Runx2-I transcription. Moreover, ERRα can act as a transcriptional activator of Runx2-I in presence of peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1α). In contrast, ERRα behaves as a negative regulator of Runx2-I transcription in presence of PGC-1β. ERα and ERRα cross-talk via a common estrogen receptor response element on the Runx2-I promoter. In addition, estrogen regulates PGC-1β that in turn is able to modulate both ERα and ERRα transcriptional activity.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403054     DOI: 10.1016/j.mce.2013.01.024

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  18 in total

Review 1.  The estrogen-related receptors (ERRs): potential targets against bone loss.

Authors:  Ling Zhang; Jiemin Wong; Jean-Marc Vanacker
Journal:  Cell Mol Life Sci       Date:  2016-08-11       Impact factor: 9.261

2.  RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis.

Authors:  Xin Yin; Xu Teng; Tianyu Ma; Tianshu Yang; Jingyao Zhang; Miaomiao Huo; Wei Liu; Yunkai Yang; Baowen Yuan; Hefen Yu; Wei Huang; Yan Wang
Journal:  Cell Death Differ       Date:  2022-05-09       Impact factor: 15.828

3.  Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.

Authors:  Tetsuya Kokabu; Taisuke Mori; Hiroshi Matsushima; Kaori Yoriki; Hisashi Kataoka; Yosuke Tarumi; Jo Kitawaki
Journal:  Cell Oncol (Dordr)       Date:  2019-01-31       Impact factor: 6.730

4.  MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.

Authors:  Li Han; Bo Liu; Lixi Jiang; Junyan Liu; Shumei Han
Journal:  Tumour Biol       Date:  2016-07-25

Review 5.  PGC-1: a key regulator in bone homeostasis.

Authors:  Haoling Chen; Wenguo Fan; Hongwen He; Fang Huang
Journal:  J Bone Miner Metab       Date:  2021-08-23       Impact factor: 2.626

6.  Identification of estrogen receptor proteins in breast cancer cells using matrix-assisted laser desorption/ionization time of flight mass spectrometry (Review).

Authors:  Zbynek Heger; Miguel Angel Merlos Rodrigo; Sona Krizkova; Ondrej Zitka; Miroslava Beklova; Rene Kizek; Vojtech Adam
Journal:  Oncol Lett       Date:  2014-02-26       Impact factor: 2.967

7.  The significance of Runx2 mediating alcohol-induced Brf1 expression and RNA Pol III gene transcription.

Authors:  Zaifa Hong; Zeng Fang; Junxia Lei; Ganggang Shi; Yanmei Zhang; Zhiming He; Wen Li B; Shuping Zhong
Journal:  Chem Biol Interact       Date:  2020-03-18       Impact factor: 5.192

Review 8.  Transcriptional Programming in Arteriosclerotic Disease: A Multifaceted Function of the Runx2 (Runt-Related Transcription Factor 2).

Authors:  Yabing Chen; Xinyang Zhao; Hui Wu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-29       Impact factor: 8.311

9.  miR-135a Inhibits the Invasion of Cancer Cells via Suppression of ERRα.

Authors:  Violaine Tribollet; Bruno Barenton; Auriane Kroiss; Séverine Vincent; Ling Zhang; Christelle Forcet; Catherine Cerutti; Séverine Périan; Nathalie Allioli; Jacques Samarut; Jean-Marc Vanacker
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

Review 10.  Role of RUNX2 in Breast Carcinogenesis.

Authors:  Daniel Wysokinski; Janusz Blasiak; Elzbieta Pawlowska
Journal:  Int J Mol Sci       Date:  2015-09-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.